Effect of Evolocumab on Coronary Plaque Phenotype and Burden …
The HUYGENS (High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study) was designed to assess whether PCSK9 inhibition in addition to high …
Effect of Evolocumab on Coronary Plaque Phenotype and Burden …
The evolocumab group achieved lower LDL-C levels (28.1 vs 87.2 mg/dL; P < 0.001). The evolocumab group demonstrated a greater increase in minimum fibrous cap thickness (+42.7 …
Assessing the impact of PCSK9 inhibition on coronary plaque …
The phase 3, multi-center, double-blind HUYGENS study will assess the impact of incremental lipid lowering with the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor, …
Effect of Evolocumab on Coronary Plaque Phenotype and Burden …
The combination of statin and evolocumab after a non-ST-segment elevation myocardial infarction produces favorable changes in coronary atherosclerosis consistent with stabilization and …
Effect of Evolocumab on Changes in Coronary Plaque Phenotype …
Patients with a non-ST elevation myocardial infarction (NSTEMI) were randomised to receive monthly evolocumab 420 mg (n=82) or placebo (n=82) via subcutaneous injection for 52 …
Stabilization of vulnerable plaque in the ACS patient: evidence …
2023年4月26日 · The results of the HUYGENS study promote the early addition of evolocumab on top of high-intensity statin in patients with NSTEMI. A combined lipid-lowering strategy is …
New Data At ESC Congress 2021 Shows Repatha® (evolocumab …
THOUSAND OAKS, Calif., Aug. 27, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data from the HUYGENS Phase 3 study showing that Repatha ® …
Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients …
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to effectively reduce LDL-C levels on a statin background. Additionally, several studies have confirmed the …
Coronary Atheroma Regression With Evolocumab in Stable and …
The reduction in percentage of atheroma volume observed with the combination of evolocumab and statin was greater in the ACS patients in HUYGENS (−2.29%) than in patients in more …
Effect of Evolocumab on Progression of Coronary Disease in …
This randomized clinical trial compares the effects of evolocumab vs placebo on change in percent atheroma volume among adult patients with angiographic